ライフサイエンスコーパス: metalloproteinase inhibitor

1 at functions as an effective, broad-spectrum metalloproteinase inhibitor.

2 lly inhibited by TIMP-3, a matrix-associated metalloproteinase inhibitor.

3 t that CT-PCPE may constitute a new class of metalloproteinase inhibitor.

4 titis, even after pretreatment with a matrix metalloproteinase inhibitor.

5 mphocytes, even in the presence of KB8301, a metalloproteinase inhibitor.

6 umor necrosis factor alpha-converting enzyme metalloproteinase inhibitor.

7 ectodomain, mimicking the effects of matrix metalloproteinase inhibitors.

8 ble by the addition of hydroxamic acid-based metalloproteinase inhibitors.

9 h proenzyme processing and interactions with metalloproteinase inhibitors.

10 was reduced significantly by treatment with metalloproteinase inhibitors.

11 IV is not inhibited by thiol-, carboxyl-, or metalloproteinase inhibitors.

12 g is inhibited at low temperature but not by metalloproteinase inhibitors.

13 ptor (EPCR) release that is not inhibited by metalloproteinase inhibitors.

14 ed bone resorption in the presence of matrix metalloproteinase inhibitors.

15 zymes (matrix metalloproteinase-1 (MMP1) and metalloproteinase inhibitor 1 (TIMP1)) were evaluated af

16 ase-2 and matrix metalloproteinase-9, tissue metalloproteinase inhibitor 1, and C-terminal propeptide

17 Matrix metalloproteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant

18 smembrane NRG-1beta and was inhibited by the metalloproteinase inhibitor 1,10-phenanthroline.

19 The metalloproteinase inhibitor 1-10-phenanthroline inhibite

20 Synthetic metalloproteinase inhibitor (1 mM) or citrate (12 mM) pr

21 uding apparent crosslinked species of tissue metalloproteinase inhibitor 3 and vitronectin, and carbo

22 nd involved in vascular integrity and TIMP3 (Metalloproteinase inhibitor 3), implicated in extracellu

23 Tissue metalloproteinase inhibitor 3, clusterin, vitronectin, a

24 R-181b expression, along with a reduction of metalloproteinase inhibitor 3.

25 of EGF receptor activation, using heparin, a metalloproteinase inhibitor and neutralizing antibodies

26 ar shedding of E-cadherin was abrogated by a metalloproteinase inhibitor and through the introduction

27 Using metalloproteinase inhibitors and A disintegrin and metal

28 Their appearance was inhibited by specific metalloproteinase inhibitors and also by lactobionate, t

29 TIMP-3 is a member of a family of metalloproteinase inhibitors and blocks A disintegrin an

30 data support the notion of combining matrix metalloproteinase inhibitors and cytotoxic agents to tre

31 hin 2 min, and this release was inhibited by metalloproteinase inhibitors and the TACE inhibitor TAPI

32 Shedding was inhibited by cycloheximide, a metalloproteinase inhibitor, and protein kinase C inhibi

33 onoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibo

34 ment can be inhibited with the use of matrix metalloproteinase inhibitors, and suggests a mechanistic

35 studies of a series of proline-based matrix metalloproteinase inhibitors are described.

36 or Con A-induced hepatitis, and that matrix metalloproteinase inhibitors are ineffective in preventi

37 These results uncover metalloproteinase inhibitors as critical stromal factors

38 Sensitivity to known matrix metalloproteinase inhibitors as well as to the endogenou

39 The addition of a matrix metalloproteinase inhibitor attenuated NKp46 downregulat

40 re, treatment with the broad-spectrum matrix metalloproteinase inhibitor batimastat (BB94) or inhibit

41 increased collagenase activity, because the metalloproteinase inhibitor batimastat had no effect.

42 EGFR, and pretreatment with a broad spectrum metalloproteinase inhibitor batimastat reduced NT-induce

43 ivation was blocked by pretreatment with the metalloproteinase inhibitor Batimastat/GM6001, the EGFR

44 the specific HB-EGF inhibitor CRM197 or the metalloproteinase inhibitors batimastat or phenanthrolin

45 Du cells was inhibited by treatment with the metalloproteinase inhibitor, batimastat.

46 atment with phenanthroline and the synthetic metalloproteinase inhibitor BB-3103 reduced the levels o

47 Mice treated with the broad-spectrum metalloproteinase inhibitor BB-94 (50 mg/kg, i.p.) showe

48 binant TIMP-1, but not TIMP-2 or a synthetic metalloproteinase inhibitor (BB-94), confers resistance

49 ate 13-acetate and can be inhibited with two metalloproteinase inhibitors, BB-94 (Batimastat) and GM6

50 nhibition of migration by the broad spectrum metalloproteinase inhibitor BB3103, demonstrated that me

51 AM17) catalytic activity, and broad spectrum metalloproteinase inhibitors block EGFR transactivation

52 appearance of soluble AR, and two different metalloproteinase inhibitors blocked AR release.

53 Synthetic metalloproteinase inhibitor, but not citrate, generated

54 0 mandibular explants with a hydroxamic acid metalloproteinase inhibitor, but not with inhibitors of

55 igel by tumor cells was largely abolished by metalloproteinase inhibitors, but not by inhibitors of o

56 It is likely that adjuvant use of matrix metalloproteinase inhibitors can significantly enhance t

57 iogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and

58 lls with an EGFR-neutralizing antibody, or a metalloproteinase inhibitor, decreased the acrolein-indu

59 Treatment with metalloproteinase inhibitors did not alter the qualitati

60 e combined use of chemotherapeutic drugs and metalloproteinase inhibitors enhances NK cell-mediated r

61 However, administration of a matrix metalloproteinase inhibitor exacerbates liver injury, in

62 expresses five members of a Fetuin A-related metalloproteinase inhibitor family but that one family m

63 In vitro, the matrix metalloproteinase inhibitor FN-439 promoted survival of

64 administration of the broad-spectrum matrix metalloproteinase inhibitor Galardin for 3 days in combi

65 n both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001).

66 Here we report that a matrix metalloproteinase inhibitor, GM-6001, improves survival

67 The metalloproteinase inhibitor, GM-6001, prevented the indu

68 Inhibition with a broad-spectrum metalloproteinase inhibitor GM6001 (100 mg/kg) ameliorat

69 Interestingly, the matrix metalloproteinase inhibitor GM6001 (ilomastat), which is

70 ndrocytes was blocked in the presence of the metalloproteinase inhibitor GM6001 and the gamma-secreta

71 f EGFR ligands, as the broad-spectrum matrix metalloproteinase inhibitor GM6001 could inhibit this ef

72 ectodomain shedding of Dsg2 with the matrix metalloproteinase inhibitor GM6001 resulted in accumulat

73 timulated cleavage is inhibited by the broad metalloproteinase inhibitor GM6001, a fact that suggests

74 growth suppression properties of the matrix metalloproteinase inhibitor GM6001.

75 carbonyl-Val-Leu-leucinal but insensitive to metalloproteinase inhibitor GM6001.

76 HB-EGF neutralizing antibody, or the matrix metalloproteinase inhibitor GM6001.

77 thylprednisolone and a broad-spectrum matrix metalloproteinase inhibitor (GM6001) did not develop emp

78 GFR) inhibitor (tyrphostin AG1478), a matrix metalloproteinase inhibitor (GM6001), or a heparin-bindi

79 A broad-spectrum metalloproteinase inhibitor, GM6001/Ilomastat, acted syn

80 gamma delta T cells, and in the presence of metalloproteinase-inhibitors >70% of gamma delta T cells

81 Recently, a class of matrix metalloproteinase inhibitors has been identified that ca

82 Specific metalloproteinase inhibitors have been used to block tum

83 Interferons, matrix metalloproteinase inhibitors, imatinib and gefitinib hav

84 rons was sufficient to confer sensitivity to metalloproteinase inhibitors in neurite outgrowth assays

85 Metalloproteinase inhibitors inactivated amylin-degradin

86 We report that metalloproteinase inhibitors, including EDTA, EGTA, and

87 Preventing the cleavage of FasL with a metalloproteinase inhibitor increased H. pylori-mediated

88 Treatment of microglia with a metalloproteinase inhibitor inhibited LRP1 shedding and

89 ression analysis showed that TIMP3, a tissue metalloproteinase inhibitor, is a common target of miR-2

90 General matrix metalloproteinase inhibitors limited the resorption of b

91 asion, the combination of TMZ and the matrix metalloproteinase inhibitor marimastat (MRM) in patients

92 e accelerated with the broad-spectrum matrix metalloproteinase inhibitor Marimastat, which may result

93 struction syndrome, establishing that matrix metalloproteinase inhibitors may be a therapeutically vi

94 The hypothesis that matrix metalloproteinase inhibitors may be useful for experimen

95 Synthetic metalloproteinase inhibitors may modify the ratio of tra

96 Matrix metalloproteinase inhibitors (MMPIs) reduce blood-brain

97 mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synt

98 or a novel series of piperazine-based matrix metalloproteinase inhibitors (MMPIs).

99 -converting enzyme, can be blocked by matrix metalloproteinase inhibitors (MMPIs).

100 is using technetium-99m-labeled broad matrix metalloproteinase inhibitor (MPI) and to determine the e

101 Technetium-99m-labeled matrix metalloproteinase inhibitor (MPI) was used for the nonin

102 mor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly develop

103 Metalloproteinase inhibitors often feature hydroxamate m

104 lucidate the effect of doxycycline, a matrix metalloproteinase inhibitor, on cardiac injury and funct

105 Incubation with a synthetic metalloproteinase inhibitor or adenoviral overexpression

106 rogation of the MMP9 catalytic activity by a metalloproteinase inhibitor or blocking antibody decreas

107 Clearance was attenuated by metalloproteinase inhibitors or antibodies to disintegri

108 nhibition of TMEFF2 shedding using synthetic metalloproteinase inhibitors or small interfering RNA ta

109 reatment of mature cortical neurons with pan-metalloproteinase inhibitors or with tissue inhibitors o

110 scular endothelial growth factor) and matrix metalloproteinase inhibitor (plasminogen activator inhib

111 Preincubation with a metalloproteinase inhibitor prevented L-selectin loss.

112 metalloproteinases with a broad-based matrix metalloproteinase inhibitor prevented LV dilation in the

113 ctional filopodial extension, whereas matrix metalloproteinase inhibitors prevented sprout extension

114 Administration of matrix metalloproteinase inhibitors prevented the signs and his

115 Doxycycline, a matrix metalloproteinase inhibitor, prevented matrix metallopro

116 of accelerated exiting, administration of a metalloproteinase inhibitor prevents macrophage efflux b

117 using TIMP or several families of synthetic metalloproteinase inhibitors reduced outflow rates.

118 Thus, metalloproteinase inhibitors regulate instructive signal

119 Addition of a specific metalloproteinase inhibitor resulted in the abrogation o

120 ideo microscopy shows that the presence of a metalloproteinase inhibitor results in a doubling of the

121 emonstrated that treating tumors with matrix metalloproteinase inhibitors results in tumor reduction

122 helial migration assays and a zinc-dependent metalloproteinase inhibitor, Ro 31-9790 (N-2-((2s)-[(hyd

123 of mitogenic signaling by PDGF-B in a matrix metalloproteinase inhibitor-sensitive fashion.

124 red ARPE-19 migration toward HGF in a matrix metalloproteinase inhibitor-sensitive manner.

125 A topical synthetic metalloproteinase inhibitor (SIMP) has been reported to

126 Metalloproteinase inhibitor studies show that constituti

127 us, localized induction of endogenous matrix metalloproteinase inhibitors, such as TIMP-4, holds prom

128 le HBEGF in cultures exposed to low O(2) and metalloproteinase inhibitor suggests that the effects of

129 this hypothesis, cotreatment of EC with the metalloproteinase inhibitor Tapi (TNF-alpha proteinase i

130 ons at this S2 cleavage site, the use of the metalloproteinase inhibitor TAPI-2, as well as small int

131 , the release of sVLDLR-N was inhibited by a metalloproteinase inhibitor, TAPI-1, while it was promot

132 Interferons, matrix metalloproteinase inhibitors, thalidomide, bevacizumab,

133 Actinonin and matlystatins are potent metalloproteinase inhibitors that comprise rare N-hydrox

134 the search for a number of synthetic matrix metalloproteinase inhibitors that could serve as potenti

135 egulated the expression of TIMP3, a secreted metalloproteinase inhibitor, that inhibited MMP14 to blo

136 and border zones at 3 months, and the matrix metalloproteinase inhibitor TIMP-4 increased dramaticall

137 e matrix metalloproteinase (MMP)-9 to tissue metalloproteinase inhibitor (TIMP)-1 ratio in the SD+Pla

138 Here, we identify the metalloproteinase inhibitor TIMP1 as a molecular switch

139 rrelates with increased plasma levels of the metalloproteinase inhibitor, TIMP1, which controls extra

140 suggests that elevated levels of the matrix metalloproteinase inhibitor, tissue inhibitor of metallo

141 ation by augmenting levels of the endogenous metalloproteinase inhibitor, tissue inhibitor of metallo

142 The ability of several specific matrix metalloproteinase inhibitors to reduce outflow facility

143 When BB-94, a matrix metalloproteinase inhibitor, was added to the culture me

144 Doxycycline, a nonselective matrix metalloproteinases inhibitor, was reported to improve th

145 A metalloproteinase inhibitor, WAY171318, reduced CCh-indu

146 metic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied.

147 osis factor-alpha stimulation was blocked by metalloproteinase inhibitors, whereas serine protease in

148 ease from cells was blocked by addition of a metalloproteinase inhibitor which concomitantly caused t

149 at, agents initially characterized as matrix metalloproteinase inhibitors which are in early stages o

150 nced by the pretreatment of tumor cells with metalloproteinase inhibitors, which increased expression

151 By reverse zymography, we have observed a metalloproteinase inhibitor with an apparent molecular w

152 Results reveal legume protein MMPIs as novel metalloproteinase inhibitors with possible pharmacologic

153 ocal delivery of Ilomastat, a general matrix metalloproteinase inhibitor, with the use of ethylene-vi